TICKERNERD
Menu
ACETACETHealthcare · Biotechnology

ACET Stock Forecast: Adicet Bio, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$7.98
+0.63% on the day

The 6 Wall Street analysts covering Adicet Bio, Inc. hold a median 12-month price target of $23 — +182.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 8 Aug 2026 — in the lower half.

Market cap
$74.6M
Ticker Nerd rank
41 / 100
Median analyst target
$23
Analysts covering
6
Total return, dividends reinvested
1W
−12.4%
1M
−7.2%
YTD
−5.2%
1Y
−27.4%
From 52W high
−52.0%
From 52W low
+30.6%
$6
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACET stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Adicet Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
78
Size
78
Growth
66
Revisions
54
Issuance
44
Volatility
39
Quality
34
Momentum
30
Value
6

Accruals (78): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (6): The shares cost a lot relative to the profits and assets behind them.

The rank is the raw material. Whether the rules would actually own Adicet Bio, Inc. — and when they’d sell — is the membership.

Wall Street

ACET stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACET, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100Oct 25Jan 26Apr 26Jul 26ACETHigh $90Median $23Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $18Median $23High $90

The green dot is the last close — the median target sits +182.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 May 2026JefferiesAssumesBuy$8.00 → $19
23 Mar 2026HC Wainwright & Co.MaintainsBuy—
13 Mar 2026GuggenheimMaintainsBuy—
21 Jan 2026HC Wainwright & Co.MaintainsBuy—
6 Jan 2026Canaccord GenuityMaintainsBuy—
7 Nov 2025HC Wainwright & Co.MaintainsBuy—
8 Oct 2025GuggenheimMaintainsBuy—
19 Sept 2025GuggenheimReiteratesBuy—
23 July 2025HC Wainwright & Co.AssumesBuy$4.00
21 Mar 2025GuggenheimReiteratesBuy—
7 Mar 2025Citizens Capital MarketsReiteratesMarket Perform—
7 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
27 Feb 2025HC Wainwright & Co.ReiteratesNeutral—
6 Feb 2025JMP SecuritiesReiteratesMarket Perform—
5 Feb 2025HC Wainwright & Co.ReiteratesNeutral—
19 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
18 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
16 Oct 2024HC Wainwright & Co.ReiteratesNeutral—
30 Sept 2024HC Wainwright & Co.ReiteratesNeutral—
20 Sept 2024WedbushReiteratesOutperform$5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ACET analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Adicet Bio, Inc. (ACET) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.5×

Cheaper than 79% of US stocks

Price / sales
—
Price / book
0.6×

Cheaper than 82% of US stocks

EV / EBITDA
0.3×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−78.1%

Higher than 16% of US stocks

Return on assets
−41.7%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ACET vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACETAdicet Bio, Inc.$74.6M
41
CRDFCardiff Oncology, Inc.$76.4M
41
ATRAAtara Biotherapeutics, Inc.$76.1M
73
GANXGain Therapeutics, Inc.$76.9M
24
ELTXElicio Therapeutics, Inc.$74.9M
34
ACRVAcrivon Therapeutics, Inc.$74.0M
61
TELOTelomir Pharmaceuticals, Inc.$79.8M
18
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACET appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ACET news & analysis

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Business Wire · 5 Aug 2026neutral

Adicet Bio reported its financial results and operational highlights for the second quarter ended June 30, 2026. The company noted progress on prula-cel, with a Phase 1 clinical update now expected in the third quarter of 2026.

Why it matters — ACET watchers would care because the update outlines the anticipated timing of the next clinical milestone for the company's lead therapy, prula-cel.

FAQ

Frequently asked questions about ACET stock

What is the ACET stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Adicet Bio, Inc. have a median 12-month price target of $23, with estimates ranging from $18 to $90. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACET stock a buy right now?

Of the 6 analysts covering Adicet Bio, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adicet Bio, Inc. 41 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACET?

As at 8 Aug 2026, Adicet Bio, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (78 of 100).

Will ACET stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +182.0% from the last close, and Ticker Nerd's factor model ranks Adicet Bio, Inc. 41 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACET stock forecast for 2030?

No analyst covering Adicet Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACET are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $90 over the next 12 months.

How has ACET stock performed over the past year?

Adicet Bio, Inc. returned -27.4% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Adicet Bio, Inc. do?

Adicet Bio, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of allogeneic gamma delta T cell therapies.

What is the latest news on ACET?

The most recent item we track (Business Wire, 5 Aug 2026): "Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates". Adicet Bio reported its financial results and operational highlights for the second quarter ended June 30, 2026. The company noted progress on prula-cel, with a Phase 1 clinical update now expected in the third quarter of 2026.

Company

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of allogeneic gamma delta T cell therapies. These off-the-shelf treatments harness gamma delta T cells to target and eliminate cancer cells through multiple mechanisms, while also facilitating innate and adaptive immune responses, and providing B-cell depletion for immune reset in autoimmune diseases. The company's novel platform emphasizes key advantages such as precise novel targeting, effective tissue homing, optimal drug exposure, and immediate availability on demand, distinguishing it from autologous therapies. Adicet Bio, Inc. focuses on delivering first-in-class solutions for patients battling cancer and autoimmune conditions, supported by a collaborative team driving innovation in the cell therapy sector. With operations in Redwood City, California; Boston, Massachusetts; and Shanghai, China, the company advances cutting-edge science toward curative potential in oncology and immunology markets.

CEO Mr. Chen Schor BA, CPA, M.B.A. · 102 employees · United States · https://www.adicetbio.com